News

OTTAWA, Ontario, March 12, 2019 /PRNewswire/ — Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced a significant expansion to their senior management team. Dr. Bozena Korczak was appointed as Chief Translational Research

OTTAWA, Feb. 12, 2019 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that researchers at the School of Pharmacy, Queen’s University Belfast, have published an article in the

OTTAWA, Jan. 29, 2019 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data evaluating the safety of OB-002H (5P12-RANTES) which is being developed as a topical microbicide

Ottawa, Canada [January 15, 2019]:    Orion Biotechnology Canada Ltd., a developer of novel medical treatments,  today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer.

OTTAWA, Canada (PRWEB)November 20, 2018 Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that it has appointed Theresa Firestone to its Board of Directors. Theresa brings more than 25 years of

OTTAWA, Oct. 31, 2018 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd., a developer of novel medical treatments, announced today the completion of a scientific advice meeting with the Medicines and Healthcare products Regulatory Agency (MHRA),